Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tonix Pharma (TNXP – Research Report), ANI Pharmaceuticals (ANIP – Research Report) and FibroGen (FGEN – Research Report).
Tonix Pharma (TNXP)
Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Tonix Pharma today and set a price target of $6.50. The company’s shares closed last Monday at $0.51, close to its 52-week low of $0.29.
According to TipRanks.com, LeBoyer is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tonix Pharma with a $6.50 average price target.
See the top stocks recommended by analysts >>
ANI Pharmaceuticals (ANIP)
Raymond James analyst Elliot Wilbur maintained a Buy rating on ANI Pharmaceuticals today and set a price target of $49.00. The company’s shares closed last Monday at $42.58.
According to TipRanks.com, Wilbur is ranked 0 out of 5 stars with an average return of
ANI Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $51.50, implying a 6.3% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $60.00 price target.
FibroGen (FGEN)
In a report released today, Paul Choi from Goldman Sachs maintained a Sell rating on FibroGen. The company’s shares closed last Monday at $17.77.
According to TipRanks.com, Choi is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for FibroGen with a $27.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TNXP:
- Tonix Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
- Tonix Pharmaceuticals announces presentations of pre-clinical data on TNX-1700
- Tonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023
- Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival
- Tonix Pharmaceuticals announces two publications of data on TNX-1500
